

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

CD8 MicroBeads, human

RRID:AB_2889920

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-045-201, RRID:AB_2889920

Antibody Information

URL: http://antibodyregistry.org/AB_2889920

Proper Citation: Miltenyi Biotec Cat# 130-045-201, RRID:AB_2889920

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: positive selection or depletion of human cytotoxic CD8+ T cells

Antibody Name: CD8 MicroBeads, human

Description: This monoclonal targets CD8

Target Organism: human

Antibody ID: AB_2889920

Vendor: Miltenyi Biotec

Catalog Number: 130-045-201

Record Creation Time: 20250819T215222+0000

Record Last Update: 20250820T002203+0000

Ratings and Alerts

No rating or validation information has been found for CD8 MicroBeads, human.

No alerts have been found for CD8 MicroBeads, human.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Geng H, et al. (2026) Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy. *Developmental cell*, 61(5), 995.

O'Reilly C, et al. (2026) LRRC15-CAR T Cells for the Treatment of Osteosarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1557.

Bernasconi-Bisio F, et al. (2025) Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML. *Molecular therapy. Oncology*, 33(1), 200949.

Chen J, et al. (2025) CD146+ CAFs mediate immunosuppression in gastric cancer via COL4A1: potential therapeutic targets. *Journal for immunotherapy of cancer*, 13(12).

Xie H, et al. (2025) Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL. *bioRxiv : the preprint server for biology*.

Libri AB, et al. (2025) Senataxin promotes recombination fidelity during antigen receptor gene diversification. *Science signaling*, 18(908), eadv8801.

Dai D, et al. (2024) Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence. *Cell reports. Medicine*, 5(5), 101550.

Hirsch T, et al. (2024) IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression. *Cell reports*, 43(7), 114401.

Moskovljevic M, et al. (2024) Cognate antigen engagement induces HIV-1 expression in latently infected CD4+ T cells from people on long-term antiretroviral therapy. *Immunity*, 57(12), 2928.

Brown AC, et al. (2023) Comprehensive epigenomic profiling reveals the extent of disease-specific chromatin states and informs target discovery in ankylosing spondylitis. *Cell genomics*, 3(6), 100306.

Barbieri L, et al. (2023) Lactate exposure shapes the metabolic and transcriptomic profile of CD8+ T cells. *Frontiers in immunology*, 14, 1101433.

Lozano-Rabella M, et al. (2023) Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(12), 2250.

Canale FP, et al. (2023) Proteomics of immune cells from liver tumors reveals immunotherapy targets. *Cell genomics*, 3(6), 100331.

Bonté PE, et al. (2022) Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. *Cell reports*, 39(10), 110916.